Drugs & Targets FDA grants accelerated approval to Elahere for platinum-resistant ovarian cancer November 18, 2022Vol.48 No.42
Drugs & Targets FDA approves Imjudo + Imfinzi and platinum-based chemo for metastatic NSCLC November 11, 2022Vol.48 No.41
Drugs & Targets FDA approves Adcetris + chemo for pediatric classical Hodgkin lymphoma November 11, 2022Vol.48 No.41
Regulatory News ODAC considers the first application based wholly on RWE methodology—and nixes it unanimously November 04, 2022Vol.48 No.40By Paul Goldberg
Drugs & Targets FDA issues draft guidance on expanded access to investigational drugs November 04, 2022Vol.48 No.40
Drugs & Targets FDA approves Imjudo in combination with Imfinzi for unresectable hepatocellular carcinoma October 28, 2022Vol.48 No.39
Drugs & Targets FDA denies marketing application for menthol e-cigarettes October 28, 2022Vol.48 No.39
In Brief Nicole Gormley named acting associate director for oncology endpoint development at FDA’s OCE October 21, 2022Vol.48 No.38
